2.06
-0.13 (-5.72%)
| Previous Close | 2.19 |
| Open | 2.16 |
| Volume | 6,780,512 |
| Avg. Volume (3M) | 2,953,788 |
| Market Cap | 251,746,416 |
| Price / Sales | 1.73 |
| Price / Book | 5.17 |
| 52 Weeks Range | |
| Earnings Date | 2 Aug 2023 - 7 Aug 2023 |
| Profit Margin | 46.54% |
| Operating Margin (TTM) | -32.78% |
| Diluted EPS (TTM) | 2.11 |
| Total Debt/Equity (MRQ) | 340.14% |
| Current Ratio (MRQ) | 3.70 |
| Operating Cash Flow (TTM) | -109.67 M |
| Levered Free Cash Flow (TTM) | -78.01 M |
| Return on Assets (TTM) | -58.61% |
| Return on Equity (TTM) | 121.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | X4 Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.5 |
| Average | 0.63 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.43% |
| % Held by Institutions | 55.70% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Stifel, 385.44%) | Buy |
| Median | 7.50 (264.08%) | |
| Low | 5.00 (HC Wainwright & Co., 142.72%) | Buy |
| Average | 7.50 (264.08%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 3.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 05 Dec 2025 | 10.00 (385.44%) | Buy | 3.80 |
| HC Wainwright & Co. | 10 Nov 2025 | 5.00 (142.72%) | Buy | 3.63 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Nov 2025 | Announcement | X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference |
| 05 Nov 2025 | Announcement | X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 27 Oct 2025 | Announcement | X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million |
| 24 Oct 2025 | Announcement | X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering |
| 23 Oct 2025 | Announcement | X4 Pharmaceuticals Announces Proposed Underwritten Public Offering |
| 17 Sep 2025 | Announcement | X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |